In Diagnostics, an integrated diagnostics biotechnology startup, recently launched its revolutionary miniaturized spectrophotometer and secured intial sales. This innovative product represents a major milestone in the field of low volume testing and demonstrates the company's commitment to advancing the field of diagnostics. The single wavelength miniaturized spectrophotometer, which is the first of its kind, is compact, portable, and easy to use. The advanced technology that powers the miniaturized spectrophotometer enables a range of low volume testing applications, including a groundbreaking liver enzymes test that measures ALT & AST from just 20 microliters of whole blood. This allows laboratory animal researchers to obtain more granular data into the progression of liver disease and better understand the underlying causes of liver disease.
The liver enzymes test represents the first application of the company's cutting-edge technology and will help advance NASH research and the development of more effective treatments. "We are proud to introduce our miniaturized spectrophotometer to the market," said Octavian Florescu, CEO of In Diagnostics. "This innovative product represents a major leap forward in the field of low volume testing and we are confident that it will be a valuable tool for our customers and help drive advancements in the diagnostics industry."
In Diagnostics invites researchers to connect with the company at Tox Expo, booth 1445, and learn more about its innovative products and services.